Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

How to Manage Workplace Stress in a Pharma R&D Environment

Posted on October 31st, 2016 by in Pharma R&D

Developing a learning culture in any organization can be a challenge, especially in the highly regulated environment of pharma R&D, where people are required to follow protocols and operating procedures. Continue reading “How to Manage Workplace Stress in a Pharma R&D Environment” »

Start-up Spotlight: Cloud Pharmaceuticals

Posted on October 28th, 2016 by in Pharma R&D

This week we are focusing on Cloud Pharmaceuticals, a drug design and development company that utilizes cloud computing in its work. Don Van Dyke, Chief Operating Officer of Cloud Pharmaceuticals, provides some insight into his company’s fascinating work. Continue reading “Start-up Spotlight: Cloud Pharmaceuticals” »

Immune Checkpoints: New Promises in Cancer Treatment

Posted on October 26th, 2016 by in Pharma R&D

Cancer immunotherapy (especially checkpoint inhibitors) is hot in the cancer therapeutics world, but we are still learning about how best to use them and in which patients. The current explosion in new cancer immunotherapies relates to braking T-cell activation: checkpoint therapies. Continue reading “Immune Checkpoints: New Promises in Cancer Treatment” »

Why you need the Right Drug Trial Participants: GERD

Posted on October 24th, 2016 by in Pharma R&D

Gastroesophageal reflux disease (GERD) is best conceptualized as a complex constellation of related syndromes rather than a single disease entity. People tend to lump the various symptoms of GERD together, when in fact the various facets of GERD, such as esophagitis, symptomatic regurgitation, and reflex cough, represent variegate pathology. Continue reading “Why you need the Right Drug Trial Participants: GERD” »

  1. 1
  2. 2
  3. 3
  4. 4